Tyra Biosciences draws industry focus with IR NMIBC research at IBCG26 retreat

Tyra Biosciences draws industry focus with IR NMIBC research at IBCG26 retreat
Tyra Biosciences in IR NMIBC research

Tyra Biosciences attracted industry attention during the IBCG26 Annual Retreat, where the company engaged with attendees over new developments shaping the future of bladder cancer treatment.

The firm presented its latest research in IR non-muscle invasive bladder cancer (NMIBC) and participated in discussions with scientific and clinical leaders. Tyra Biosciences continues to focus on innovative approaches in bladder cancer care.

Tyra Biosciences previously began the SURF302 trial to evaluate a new therapy for intermediate-risk non-muscle invasive bladder cancer. The company has also launched the BEACH301 study to explore selective FGFR3 inhibition in achondroplasia. Both studies reflect Tyra’s ongoing focus on targeted treatment innovation.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.